Cannabis for Opioid Withdrawal Tied to Lower Opioid Use

People who deliberately used cannabis to blunt the symptoms of opioid withdrawal had more than twice the odds of reporting that they cut back on opioids, according to a new federally funded study of Vancouver residents who use fentanyl, heroin and other drugs from the unregulated supply. The link was strongest among participants living with significant pain. The researchers are careful to frame it as an association, not proof that cannabis caused the reductions.

The analysis, published June 24, 2026 in the Journal of Cannabis Research, drew on questionnaires completed between December 2019 and November 2021 by 197 people who use unregulated opioids and also use cannabis. About 45 percent said they had used cannabis to manage opioid withdrawal in the previous six months. Within that group, roughly two-thirds reported needing fewer opioids during stretches when they were using cannabis. After adjusting for age, gender, race, pain and several other factors, that link held.

The pain signal, and its uncertainty

The clearest effect appeared in people already in pain. Among the roughly half of participants reporting moderate to severe pain, using cannabis for withdrawal was associated with more than six times the odds of cutting opioid use. Among those with little or no pain, there was no significant link, and a statistical test confirmed that pain itself changed the relationship.

That six-fold figure carries a wide band of uncertainty. The study’s confidence interval stretched from about two-and-a-half to nearly twenty, a spread that reflects how few people fell into each subgroup. The direction of the effect is clear; its true magnitude is not well pinned down. The honest takeaway is that pain appears to matter here, not that cannabis reliably produces a six-fold change.

What the design can and can’t show

This was a cross-sectional study — a single snapshot rather than a trial that randomly assigns some people to cannabis and others to a placebo. That structure can show that two things move together; it cannot establish which, if either, drives the other. The authors say so plainly, noting that “causality and the direction of associations cannot be established.”

Two other limits are worth keeping in view. Both the cannabis use and the opioid reductions were self-reported, with no drug testing to confirm them and no measure of how far opioid use actually fell, so there is no way to tell whether the reported reductions were large enough to matter clinically. And the evidence base is genuinely mixed: the same paper points to a 2021 study in which the odds of opioid use roughly doubled on days people also used cannabis, the opposite of a substitution effect. The strongest experimental support the authors cite comes from trials of purified cannabidiol given at doses far higher than street or store-bought cannabis typically delivers.

None of that makes the finding trivial. It adds a specific data point — intentional use of cannabis for withdrawal, rather than casual co-use — to a growing observational literature that includes reports of inhaled cannabis and near-total opioid cessation in chronic pain and studies asking whether legalization curbs opioid misuse.

Why the question keeps coming back

The backdrop is a drug-poisoning crisis that has killed more than 56,000 people in Canada since 2016, the large majority from fentanyl and other non-pharmaceutical opioids. Withdrawal is a dangerous pivot point: unmanaged symptoms push people back toward an increasingly toxic supply, raising the risk of overdose. Existing treatments such as methadone and buprenorphine work but are hard for many people to start and stay on, which is why researchers keep testing lower-barrier options — including cannabis — as a harm-reduction tool alongside chronic-pain care.

The work was funded by the U.S. National Institutes of Health and the Canadian Institutes of Health Research. It also carries conflict-of-interest disclosures a careful reader should note: one author holds a University of British Columbia professorship in cannabis science endowed partly by arm’s-length gifts from Canopy Growth (CGC ), a licensed cannabis producer, and the provincial government, and another disclosed paid consulting and speaking fees from a private medical-cannabis company.

The authors’ own conclusion is measured. Their data, they write, do not offer conclusive evidence for using cannabis in opioid withdrawal; what it justifies is controlled experimental testing in people who are both in withdrawal and in pain. Until those trials are run, the finding is best read as a reason to study cannabis more rigorously as a potential treatment aid in opioid dependence, not as a clinical recommendation.

References:

^{1. McAdam, Erica; Reddon, Hudson; Socías, M. Eugenia; Lake, Stephanie; Hayashi, Kanna; DeBeck, Kora; Walsh, Zach; and Milloy, M-J, “Self-reported cannabis use to manage opioid withdrawal symptoms and reductions in opioid use among people who use unregulated opioids: a cross-sectional analysis” (2026). Journal of Cannabis Research. https://doi.org/10.1186/s42238-026-00458-0}